Confirmed Control Closed Transaction verified Gastrointestinal PharmaceuticalsSpecialty Pharmaceuticals
Sucampo Pharmaceuticals, Inc. acquired by Mallinckrodt
Mallinckrodt acquired Sucampo Pharmaceuticals, Inc., a gastrointestinal pharmaceuticals brand on Dec 26, 2017. The transaction value is shown as USD 1.2bn. The current comp implies EV / revenue of 4.6x. Public sources confirm the deal; valuation inputs may include estimates where transaction materials do not disclose the full economics.
Transaction summary
- Target
- Sucampo Pharmaceuticals, Inc.
- Acquirer
- Mallinckrodt
- Seller
- -
- Announced
- 2017-12-26
- Geography
- -
- Tags
- Gastrointestinal PharmaceuticalsSpecialty Pharmaceuticals
- Type
- Acquisition
- Deal type
- Control
- Stake acquired
- -
- First added
- 2026-06-19
- Latest update
- 2026-06-19
Value and multiples
Price / value
USD 1.2B
Transaction value | USD
Basis: Public source
EV / revenue
4.6x
Period not stated
Basis: FundComb estimate
EV / EBITDA
-
EBITDA basis not stated
Basis: FundComb estimate
Basis
- USD 1.2bn transaction value is treated as publicly disclosed or derived directly from public source data.
- EV / revenue is shown as 4.6x based on the available comp inputs.
- Revenue and multiple inputs are not fully disclosed in public transaction materials reviewed; treat the multiple as an estimate.
Source summary
No public source summary has been published for this transaction yet.